Sydney-based medical technology company, AllVascular, is pleased to announce the appointment of Professor Govindaranjan Narayanan to its medical advisory board.
The distinguished Dr Narayanan is a Professor of Radiology at the Herbert Wertheim College of Medicine at Florida International University in the United States. He is the Chief of Interventional Oncology at the Miami Cancer Institute and practices at the Miami Cardiac and Vascular Institute, both part of Baptist Health of South Florida.
AllVascular is the developer and manufacturer of proprietary vascular access platform technology platform, the Arterial Access System (AVAS®). The AVAS® is an implantable medical device that enables the isolated and targeted delivery of therapeutic agents such as chemotherapy directly to tumour sites. The AVAS® can be applied to the treatment of many solid cancers including liver, pancreatic, cholangiocarcinoma and pelvic organ.
Chairman of AllVascular, Dr Alan Robertson said: “We are delighted and honoured to welcome Dr Narayanan to our Medical Board as he brings impeccable credentials to our organisation at a pivotal time. The AVAS® is approved for use in Australia, New Zealand, Europe and the UK and we have made a submission to the FDA for Breakthrough Designation.
“We are focused on bringing our AVAS® product to markets around the world so that clinicians and their patients have access to new approaches to the intractable challenges presented by liver and pancreatic cancers.
“Dr Narayanan will play an instrumental role on our journey and I look forward to working with him and the intellectual and scientific rigour he brings to AllVascular” said Dr Robinson.
Dr Narayanan’s clinical expertise includes trans-arterial and ablative technologies. He is a pioneer in his field, having developed the technique of percutaneous irreversible electroporation (IRE) of the pancreas. His primary clinical research interests include pancreatic, liver and colon cancer.
Commenting on his appointment, Dr Narayanan said: “AllVascular’s AVAS® product can make a real and meaningful difference to the targeted treatment of colorectal liver cancer. I look forward to making a meaningful contribution at AllVascular.”
Dr Narayanan strengthens the 7-strong AllVascular Medical Advisory Board, alongside Professor Stephen Clarke (Medical Oncologist), Professor Nick Pavlakis (Medical Oncologist), Professor Thomas Hugh (Hepatobiliary Surgeon), Professor Rodney Lane (Vascular Surgeon), Dr Chris Rogan (Interventional Radiologist) and Clinical Professor Gavin Marx (Medical Oncologist).
AllVascular recently secured $5m in pre-IPO funding following a successful capital raise with Blue Ocean Equities in Australia. The funds will be used to accelerate the development and commercialisation of the AVAS®, including the commencement of clinical studies in both pancreatic and liver cancers, with an application for Breakthrough Designation status with the FDA in the US.
Marketing of the AVAS® has commenced in Australia and Germany, with the UK and France expected to commence soon. AllVascular is targeting an IPO in 2022.
…ends…
